Logo

Merck's Keytruda (pembrolizumab) + Chemotherapy Receive NMPA's (CFDA) Approval for 1L Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Share this

Merck's Keytruda (pembrolizumab) + Chemotherapy Receive NMPA's (CFDA) Approval for 1L Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Shots:

  • The approval is based on P-III KEYNOTE-189 trial assessing Keytruda + pemetrexed & Pt CT in patients with 1L metastatic non-sq NSCLC- with no EGFR or ALK genomic tumor aberrations regardless of PD-L1 tumor expression status
  • The P-III KEYNOTE-189 trial resulted in improvement in OS- reduction in the risk of death by half- improvement in PFS
  • Keytruda (pembrolizumab) 100mg is an anti-PD-1 therapy involves blocking of the interaction between PD-1 and its ligands i.e PD-L1 & PD- L2 and is evaluated in 900 trial globally in oncology

Ref: Merck & Co. | Image: Merck

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions